Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized trial of oral LNP023 versus eculizumab in PNH
2019-004665-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Novartis. Primary endpoint: Sustained hemoglobin increase ≥2 g/dL without transfusions. Started Sep 2020; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-004665-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004665-40.